Elevations in Creatine Kinase are Not Related to the Choice or Dose of Statins in Patients Taking Colchicine 0.5 mg Daily: Insights from the LoDoCo2 Trial
Clin Drug Investig
.
2023 Jul;43(7):575-577.
doi: 10.1007/s40261-023-01287-2.
Epub 2023 Jul 20.
Authors
Amber van Broekhoven
1
,
John W Eikelboom
2
,
Stefan M Nidorf
3
4
,
Arend Mosterd
5
6
,
Jan H Cornel
7
8
9
;
LoDoCo2 investigators
Affiliations
1
Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands.
2
Department of Medicine, McMaster University, Hamilton, ON, Canada.
3
Heart and Vascular Research Institute of Western Australia, Perth, Australia.
4
GenesisCare Western Australia, Perth, Australia.
5
Dutch Network for Cardiovascular Research (WCN), Utrecht, The Netherlands.
6
Department of Cardiology, Meander Medical Centre, Amersfoort, The Netherlands.
7
Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands.
[email protected]
.
8
Dutch Network for Cardiovascular Research (WCN), Utrecht, The Netherlands.
[email protected]
.
9
Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands.
[email protected]
.
PMID:
37470947
DOI:
10.1007/s40261-023-01287-2
No abstract available
Publication types
Letter
MeSH terms
Colchicine / adverse effects
Creatine Kinase
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
Substances
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Creatine Kinase
Colchicine